Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study
Atherosclerosis
· Elsevier
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Читать у издателя →
Цитирование
Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study. // Atherosclerosis. – URL: https://www.sciencedirect.com/science/article/pii/S0021915026012785?dgcid=rss_sd_all
Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study. Atherosclerosis. https://www.sciencedirect.com/science/article/pii/S0021915026012785?dgcid=rss_sd_all
“Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study.” Atherosclerosis.
@article{article37088,
title = {Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study},
journal = {Atherosclerosis},
url = {https://www.sciencedirect.com/science/article/pii/S0021915026012785?dgcid=rss_sd_all}
}